• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Th1 和 Th17 细胞因子在小儿炎症性肠病中的分隔表达。

Compartmentalized expression of Th1 and Th17 cytokines in pediatric inflammatory bowel diseases.

机构信息

INSERM, UMR989, Université Paris Descartes, Sorbonne Paris Cité, Hôpital Necker-Enfants Malades, Assistance-Publique-Hopitaux de Paris, Paediatric Gastroenterology Unit, Paris, France.

出版信息

Inflamm Bowel Dis. 2012 Jul;18(7):1260-6. doi: 10.1002/ibd.21905. Epub 2011 Oct 12.

DOI:10.1002/ibd.21905
PMID:21994045
Abstract

BACKGROUND

Interleukin (IL)-23, IL-17A, IL-17F, and interferon-gamma (IFN-γ) are important mediators of inflammatory colitis and are potential therapeutic targets in inflammatory bowel disease (IBD). Their expression profile in the different parts of normal noninflammatory intestine is unclear and their changes during pathology have not yet been addressed in pediatric IBD patients.

METHODS

We quantified the transcriptional expression of IL-23, IL-12, IL-17A, IL-17F, IL-6, and IL-10 in healthy, noninflammatory duodenum, ileum, and colon and in inflamed and noninflamed biopsies of pediatric patients with Crohn's disease (CD) and ulcerative colitis (UC).

RESULTS

In healthy tissue, expression of IL-17A is highest in the ileum, with IFN-γ expression lowest in the colon. Compared to healthy sections, CD patients displayed increased IL-12p35 and IFN-γ levels in noninflamed ileum and colon, respectively. Modifications of cytokine expression between noninflamed and inflamed tissues was characterized by increased IL-17A in UC colon, IFN-γ in CD colon, and IL-17A, IFN-γ and IL-6 in CD ileum. Elevated IL-17A levels were positively correlated with IFN-γ in both inflammatory CD and UC but IL-17A and IFN-γ were correlated with IL-23p19 in CD ileum only.

CONCLUSIONS

The expression of Th1 and Th17 cytokines varies along the intestine, indicating local specific regulation mechanisms. However, the cytokine expression patterns in the same tissue depends on the pathology, with a Th1 or a Th17 profile in the colon of CD and UC patients, respectively, and a Th1/Th17 profile in the ileum of CD patients. This indicates overlapping but distinct immune mechanisms driving intestinal inflammation in these two pathologies.

摘要

背景

白细胞介素(IL)-23、IL-17A、IL-17F 和干扰素-γ(IFN-γ)是炎症性结肠炎的重要介质,也是炎症性肠病(IBD)的潜在治疗靶点。它们在正常非炎症性肠道的不同部位的表达谱尚不清楚,其在儿科 IBD 患者中的病理变化尚未得到解决。

方法

我们定量检测了健康、非炎症性十二指肠、回肠和结肠以及克罗恩病(CD)和溃疡性结肠炎(UC)患儿的炎症和非炎症活检组织中 IL-23、IL-12、IL-17A、IL-17F、IL-6 和 IL-10 的转录表达。

结果

在健康组织中,IL-17A 在回肠中的表达最高,而 IFN-γ 在结肠中的表达最低。与健康组织相比,CD 患者的非炎症性回肠和结肠中分别显示出 IL-12p35 和 IFN-γ 水平增加。非炎症组织和炎症组织之间细胞因子表达的变化特征是 UC 结肠中 IL-17A 增加,CD 结肠中 IFN-γ 增加,CD 回肠中 IL-17A、IFN-γ 和 IL-6 增加。CD 中炎症和非炎症组织中升高的 IL-17A 水平与 IFN-γ 呈正相关,但仅在 CD 回肠中,IL-17A 和 IFN-γ 与 IL-23p19 相关。

结论

Th1 和 Th17 细胞因子的表达沿肠道变化,表明存在局部特定的调节机制。然而,同一组织中的细胞因子表达模式取决于病理学,CD 和 UC 患者的结肠呈 Th1 或 Th17 表型,CD 患者的回肠呈 Th1/Th17 表型。这表明在这两种疾病中,有重叠但不同的免疫机制驱动肠道炎症。

相似文献

1
Compartmentalized expression of Th1 and Th17 cytokines in pediatric inflammatory bowel diseases.Th1 和 Th17 细胞因子在小儿炎症性肠病中的分隔表达。
Inflamm Bowel Dis. 2012 Jul;18(7):1260-6. doi: 10.1002/ibd.21905. Epub 2011 Oct 12.
2
TH1 and TH17 interactions in untreated inflamed mucosa of inflammatory bowel disease, and their potential to mediate the inflammation.TH1 和 TH17 细胞在炎症性肠病未治疗的炎症黏膜中的相互作用,及其介导炎症的潜力。
Cytokine. 2011 Dec;56(3):633-40. doi: 10.1016/j.cyto.2011.08.036. Epub 2011 Sep 25.
3
Role of the novel Th17 cytokine IL-17F in inflammatory bowel disease (IBD): upregulated colonic IL-17F expression in active Crohn's disease and analysis of the IL17F p.His161Arg polymorphism in IBD.新型Th17细胞因子白细胞介素-17F(IL-17F)在炎症性肠病(IBD)中的作用:活动期克罗恩病患者结肠中IL-17F表达上调及IBD中IL17F基因p.His161Arg多态性分析
Inflamm Bowel Dis. 2008 Apr;14(4):437-45. doi: 10.1002/ibd.20339.
4
The increased expression of IL-23 in inflammatory bowel disease promotes intraepithelial and lamina propria lymphocyte inflammatory responses and cytotoxicity.在炎症性肠病中,IL-23 的表达增加促进了上皮内和固有层淋巴细胞的炎症反应和细胞毒性。
J Leukoc Biol. 2011 Apr;89(4):597-606. doi: 10.1189/jlb.0810456. Epub 2011 Jan 7.
5
TL1A as a Potential Local Inducer of IL17A Expression in Colon Mucosa of Inflammatory Bowel Disease Patients.TL1A作为炎症性肠病患者结肠黏膜中IL17A表达的潜在局部诱导因子。
Scand J Immunol. 2015 Oct;82(4):352-60. doi: 10.1111/sji.12324.
6
Mucosal cytokine gene expression profiles as biomarkers of response to infliximab in ulcerative colitis.黏膜细胞因子基因表达谱作为溃疡性结肠炎中对英夫利昔单抗反应的生物标志物
Scand J Gastroenterol. 2012 May;47(5):538-47. doi: 10.3109/00365521.2012.667146.
7
Expression of interleukin-12-related cytokine transcripts in inflammatory bowel disease: elevated interleukin-23p19 and interleukin-27p28 in Crohn's disease but not in ulcerative colitis.炎症性肠病中白细胞介素-12相关细胞因子转录本的表达:白细胞介素-23p19和白细胞介素-27p28在克罗恩病中升高,但在溃疡性结肠炎中未升高。
Inflamm Bowel Dis. 2005 Jan;11(1):16-23. doi: 10.1097/00054725-200501000-00003.
8
Expression of inflammatory genes in the colon of ulcerative colitis patients varies with activity both at the mRNA and protein level.溃疡性结肠炎患者结肠中炎症基因的表达在 mRNA 和蛋白质水平上均随其活性变化而变化。
Eur Cytokine Netw. 2013 Jul-Sep;24(3):130-8. doi: 10.1684/ecn.2013.0343.
9
Increased IL-17A/IL-17F expression ratio represents the key mucosal T helper/regulatory cell-related gene signature paralleling disease activity in ulcerative colitis.白细胞介素-17A/白细胞介素-17F表达比率升高代表了溃疡性结肠炎中与黏膜辅助性T细胞/调节性细胞相关的关键基因特征,且与疾病活动平行。
J Gastroenterol. 2017 Mar;52(3):315-326. doi: 10.1007/s00535-016-1221-1. Epub 2016 May 13.
10
Pediatric Crohn disease is characterized by Th1 in the terminal ileum and Th1/Th17 immune response in the colon.小儿克罗恩病的特征是末端回肠的 Th1 和结肠的 Th1/Th17 免疫应答。
Eur J Pediatr. 2018 Apr;177(4):611-616. doi: 10.1007/s00431-017-3076-8. Epub 2018 Feb 3.

引用本文的文献

1
Interleukin-10 production by innate lymphoid cells restricts intestinal inflammation in mice.天然淋巴细胞产生白细胞介素-10可限制小鼠肠道炎症。
Mucosal Immunol. 2025 Jun;18(3):643-655. doi: 10.1016/j.mucimm.2025.02.005. Epub 2025 Feb 21.
2
Oral Delivery of miR146a Conjugated to Cerium Oxide Nanoparticles Improves an Established T Cell-Mediated Experimental Colitis in Mice.与氧化铈纳米颗粒偶联的miR146a经口服给药可改善已建立的小鼠T细胞介导的实验性结肠炎。
Pharmaceutics. 2024 Dec 9;16(12):1573. doi: 10.3390/pharmaceutics16121573.
3
Ulcerative colitis: molecular insights and intervention therapy.
溃疡性结肠炎:分子见解与干预治疗。
Mol Biomed. 2024 Oct 10;5(1):42. doi: 10.1186/s43556-024-00207-w.
4
Comparing the Effects of Anti-TNF Agent and Ustekinumab on Small Bowel Inflammation in Crohn's Disease: Inverse Probability Weighting With Stabilized Weights of Propensity Scores.比较抗TNF药物与优特克单抗对克罗恩病小肠炎症的影响:倾向得分稳定权重的逆概率加权法
Crohns Colitis 360. 2024 May 14;6(2):otae033. doi: 10.1093/crocol/otae033. eCollection 2024 Apr.
5
Clinical effectiveness and safety of ustekinumab in youth with refractory inflammatory bowel disease: A retrospective cohort study.优特克单抗治疗难治性炎症性肠病青年患者的临床疗效与安全性:一项回顾性队列研究。
Saudi J Gastroenterol. 2025 Mar 1;31(2):59-67. doi: 10.4103/sjg.sjg_7_24. Epub 2024 Apr 10.
6
Molecular analyses of ADAMTS-1, -4, -5, and IL-17 a cytokine relationship in patients with ulcerative colitis.ADAMTS-1、-4、-5 和白细胞介素-17A 细胞因子在溃疡性结肠炎患者中的分子分析。
BMC Gastroenterol. 2023 Oct 5;23(1):345. doi: 10.1186/s12876-023-02985-z.
7
Are We Ready to Reclassify Crohn's Disease Using Molecular Classification?我们准备好使用分子分类法对克罗恩病进行重新分类了吗?
J Clin Med. 2023 Sep 5;12(18):5786. doi: 10.3390/jcm12185786.
8
Therapeutic potential of mesenchymal stem/stromal cells (MSCs)-based cell therapy for inflammatory bowel diseases (IBD) therapy.间充质干细胞(MSCs)为基础的细胞疗法治疗炎症性肠病(IBD)的治疗潜力。
Eur J Med Res. 2023 Jan 27;28(1):47. doi: 10.1186/s40001-023-01008-7.
9
IL-23 Blockade in Anti-TNF Refractory IBD: From Mechanisms to Clinical Reality.抗 TNF 治疗抵抗的 IBD 中 IL-23 阻断:从机制到临床现实。
J Crohns Colitis. 2022 May 11;16(Supplement_2):ii54-ii63. doi: 10.1093/ecco-jcc/jjac007.
10
Therapeutic drug monitoring for biological medications in inflammatory bowel disease.炎症性肠病生物药物的治疗药物监测。
Saudi J Gastroenterol. 2022 Sep-Oct;28(5):322-331. doi: 10.4103/sjg.sjg_3_22.